Every material Form 8-K MEDIFAST INC has filed with the SEC since July 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Medifast reported third quarter 2026 revenue of $72.0 million, down 19.4% from $89.4 million a year earlier, as active earning coaches fell 47.7% to 10,200. The company posted a net loss of $17.5 million, or $1.57 per share, compared with a loss of $2.3 million, or $0.21 per share, a year earlier, and it expects coach numbers to keep declining through the end of 2026. For shareholders, the filing shows weaker sales and a larger loss, partly driven by Catalyst Restructuring charges, with full-year 2026 loss per share guidance of $1.80 to $2.05.
Revenue $72.0 million, down 19.4% from $89.4 million; active earning coaches 10,200, down 47.7% from 19,500
Net loss $17.5 million, or $1.57 per diluted share; non-GAAP adjusted net loss $2.1 million, or $0.19 per share
Fourth quarter 2026 revenue guided to $55 million to $75 million; full-year 2026 revenue guided to $280 million to $300 million
Cash, cash equivalents and investment securities of $172.5 million with no debt as of September 30, 2026
Medifast reported second quarter 2026 revenue of $76.4 million, down 27.6% from $105.6 million a year earlier, and a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million, or $0.22 per share, in the prior-year quarter. The company expects full year 2026 revenue of $270 million to $300 million and a loss of $0.25 to $1.75 per share, so shareholders face continued losses and lower sales.
Active earning coaches fell 48.7% to 11,700 from 22,800 a year earlier, and the company expects the number to keep declining in 2026.
Gross profit margin was 69.9%, down from 72.6%, and loss from operations was $4.3 million versus $1.1 million a year earlier.
Full year 2026 guidance: revenue of $270 million to $300 million and loss per share of $0.25 to $1.75.
Third quarter 2026 guidance: revenue of $60 million to $80 million and loss per share of $0.15 to $0.65, excluding one-time Catalyst program costs.
Medifast, Inc. announced on July 17, 2026 that its wholly owned subsidiary OPTAVIA is being rebranded as Trilivy, described as a comprehensive metabolic health system. The company also introduced newly formulated meal replacements, with the planned debut of these Fuelings in August. The filing, which furnishes a press release, includes no revenue, earnings, or guidance figures, so its direct financial effect on shareholders is not quantified.
Rebranding of OPTAVIA to Trilivy announced July 17, 2026, via a press release furnished as Exhibit 99.1
Trilivy Reset Fueling line, enhanced with MetaVantage Technology, accompanies the brand launch
Newly formulated meal replacements, called Fuelings, are planned to debut in August
The filing contains no financial results, guidance, or dollar figures
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MEDIFAST INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →